Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Q32 Bio (QTTB) Common Equity (2017 - 2025)

Q32 Bio (QTTB) has 9 years of Common Equity data on record, last reported at $42.0 million in Q4 2025.

  • For Q4 2025, Common Equity rose 640.33% year-over-year to $42.0 million; the TTM value through Dec 2025 reached $42.0 million, up 640.33%, while the annual FY2025 figure was $42.0 million, 640.33% up from the prior year.
  • Common Equity reached $42.0 million in Q4 2025 per QTTB's latest filing, up from -$18.4 million in the prior quarter.
  • Across five years, Common Equity topped out at $266.3 million in Q1 2022 and bottomed at -$182.9 million in Q4 2023.
  • Average Common Equity over 5 years is $43.6 million, with a median of $25.9 million recorded in 2024.
  • The widest YoY moves for Common Equity: up 640.33% in 2025, down 200.84% in 2025.
  • A 5-year view of Common Equity shows it stood at $169.7 million in 2021, then plummeted by 177.05% to -$130.7 million in 2022, then tumbled by 39.94% to -$182.9 million in 2023, then surged by 103.1% to $5.7 million in 2024, then soared by 640.33% to $42.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $42.0 million in Q4 2025, -$18.4 million in Q3 2025, and -$12.2 million in Q2 2025.